Kira Pharmaceuticals

Dec 10, 2024

Kira Pharmaceuticals Presents Updated Data of Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH) at American Society of Hematology (ASH) 2024 Demonstrating Long-Term Safety and Efficacy

Jun 17, 2024

Kira Pharmaceuticals Presents Positive Results of KP104 Phase 2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Study at European Hematology Association (EHA) Congress 2024 Demonstrating Long-term Safety and Efficacy

May 16, 2024

Kira Pharmaceuticals to Present Positive Long-term Results of KP104 in Phase 2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Study at the 2024 European Hematology Association (EHA) Hybrid Congress

Feb 23, 2021

Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, China

Feb 02, 2021

Kira Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial for P014, a Bifunctional Biologic Medicine

Jan 12, 2021

Kira Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

Nov 12, 2020

Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases